Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2011

View Archived Issues

Long-term daclizumab therapy analyzed in patients with MS

Phosphodiesterase 5 inhibitor improves portal hypertension in open-label trial

Boceprevir improves hepatitis C treatment in patients coinfected with HIV

Ondansetron is effective in treating diarrhea-predominant irritable bowel syndrome

Telormedix reports promising preclinical data on topical skin cancer treatment

Clinuvel's Scenesse shows clinically relevant prophylactic effect in EPP

Chelsea Therapeutics reports interim results from phase II study of CH-4051

New mTOR inhibitors disclosed by Auspex Pharmaceuticals

RespiVert prepares novel MAP kinase p38 inhibitors

Life Sciences Research Partners and Flanders' VIB claim new cell-based ischemia therapy

Tibotec presents novel HIV integrase inhibitors

Senesco initiates dosing in phase Ib/IIa SNS01-T study

Tetraphase Pharmaceuticals synthesizes new antibacterial agents

Avanir Pharmaceuticals enrolls first patient in PRIME study

Optimer files NDS for Dificid in Canada

Interim analysis of MDV-3100 prostate cancer study shows beneficial survival data

BMS and Aslan enter agreement for anticancer compound

RedHill Biopharma plans RHB-102 bioequivalence study

Korean company patents new glucagon GLP-1 receptor agonists

Novel casein kinase II inhibitors reported by BMS

Researchers at Lilly describe novel cannabinoid CB2 receptor agonists

PharmaGap plans in vivo efficacy testing of GAP-107B8

FDA accepts VIVUS' resubmitted Qnexa NDA

Atlab Pharma and BZL Biologics enter licensing agreement for [177Lu]-J591

Discovery Labs' lucinactant gains European orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...